Please try another search
As of August 27, 2015, Receptos, Inc. was acquired by Celgene Corporation. Receptos, Inc. discovers, develops, and commercializes therapeutics in immune disorders. It develops RPC4046, a monoclonal antibody, which is in phase II trials for the treatment of eosinophilic esophagitis and immune-mediated disorders. The company also offers ozanimod, an oral therapy for the treatment of relapsing multiple sclerosis. Additionally, it is involved in a research and development program for preclinical studies of Type 2 diabetes. The company was formerly known as Receptor Pharmaceuticals, Inc. and changed its name to Receptos, Inc. in January 2009. Receptos, Inc. was founded in 2008 and is based in San Diego, California.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review